ClinicalTrials.gg
Sign In
Drug

Selpercatinib clinical trials

Also written LOXO-292, LY3527723 and Retevmo.

studies test it
28
open now
5
in phase 3
3
first study started
2016

How each study uses selpercatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the selpercatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
8 May 2020 · RETEVMO · NDA 213246 (FDA, Drugs@FDA)
European Union
11 Feb 2021 · Retsevmo · EMEA/H/C/005375 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Selpercatinib
27
RET Kinase Inhibitor LOXO-292
5
Retsevmo
3

Brand

Retevmo
7

Development codes

LOXO-292
22
LY3527723
19
WHO 10967
4

Studies by the year they started

28 studies that test it; most in 2021 (6)

Studies that test selpercatinib, by start year
YearStudies
20161
20172
20184
20194
20204
20216
20222
20232
20251
20262

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
14
Phase 2
10
Phase 3
3
Phase 4
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Non-Small-Cell Lung
5
Thyroid Neoplasms
3
Histiocytosis, Langerhans-Cell
1
Ependymoma
1
Renal Insufficiency
1
Thyroid Cancer, Papillary
1
Neoplasms
1

Who runs them

Industry 19 · Other 9

Eli Lilly and Company (14) · Loxo Oncology, Inc. (5) · National Cancer Institute (NCI) (2) · SWOG Cancer Research Network (2) · M.D. Anderson Cancer Center (1) · University of Oklahoma (1) · Fujian Medical University (1) · Massachusetts General Hospital (1)

Often tested with

Tested in the same studies.

Erdafitinib (2) · Larotrectinib (2) · Olaparib (2) · Palbociclib (2) · Vemurafenib (2) · Dabrafenib (2) · Trametinib (2) · Lenvatinib (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4

Studies that test selpercatinib.

Studies

Open first, then newest update. How each study uses selpercatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 28

See all 28 studies that test selpercatinib →

Given beside what is tested · 5 — selpercatinib is usual care or a partner of the new treatment

Codes

What other systems call selpercatinib · ClinicalTrials.gg INT001233

  • MeSH (NLM) C000656166selpercatinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) CEGM9YBNGDSELPERCATINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2370147One source FDA
  • Wikidata Q96405266selpercatinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C134987SelpercatinibOne source FDA
  • DrugBank DB15685One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.